- $372.56m
- $366.83m
- $132.58m
- 92
- 29
- 48
- 57
Annual income statement for SurModics, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2019 September 30th | 2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 100 | 94.9 | 105 | 100 | 133 |
| Cost of Revenue | |||||
| Gross Profit | 86.4 | 79.5 | 88.5 | 79.6 | 108 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 93.6 | 96.1 | 98.4 | 122 | 127 |
| Operating Profit | 6.47 | -1.25 | 6.7 | -22.1 | 5.15 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 7.56 | -1.45 | 6.35 | -22.5 | 2.49 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 7.59 | 1.12 | 4.24 | -27.3 | -1.54 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 7.59 | 1.12 | 4.24 | -27.3 | -1.54 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 7.59 | 1.12 | 4.24 | -27.3 | -1.54 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.593 | 0.081 | 0.525 | -1.96 | -0.05 |